Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome |
| |
Authors: | Dorien J A Lobbezoo Roel J W van Kampen Adri C Voogd M Wouter Dercksen Franchette van den Berkmortel Tineke J Smilde Agnes J van de Wouw Frank P J Peters Johanna M G H van Riel Natascha A J B Peters Maaike de Boer George F Borm Vivianne C G Tjan-Heijnen |
| |
Institution: | 1. Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands 2. Máxima Medical Center, Eindhoven, The Netherlands 3. Atrium Medical Center Parkstad, Heerlen, The Netherlands 4. Jeroen Bosch Hospital, Den Bosch, The Netherlands 5. VieCuri Medical Center, Venlo, The Netherlands 6. Orbis Medical Center, Sittard, The Netherlands 7. St Elisabeth Hospital, Tilburg, The Netherlands 8. St Jans Hospital, Weert, The Netherlands 9. Radboud University Medical Center, Nijmegen, The Netherlands
|
| |
Abstract: | Contrary to the situation in early breast cancer, little is known about the prognostic relevance of the hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) in metastatic breast cancer. The objectives of this study were to present survival estimates and to determine the prognostic impact of breast cancer subtypes based on HR and HER2 status in a recent cohort of metastatic breast cancer patients, which is representative of current clinical practice. Patients diagnosed with metastatic breast cancer between 2007 and 2009 were included. Information regarding patient and tumor characteristics and treatment was collected. Patients were categorized in four subtypes based on the HR and HER2 status of the primary tumor: HR positive (+)/HER2 negative (?), HR+/HER2+, HR?/HER2+ and triple negative (TN). Survival was estimated using the Kaplan–Meier method. Cox proportional hazards model was used to determine the prognostic impact of breast cancer subtype, adjusted for possible confounders. Median follow-up was 21.8 months for the 815 metastatic breast cancer patients included; 66 % of patients had the HR+/HER2? subtype, 8 % the HR?/HER2+ subtype, 15 % the TN subtype and 11 % the HR+/HER2+ subtype. The longest survival was observed for the HR+/HER2+ subtype (median 34.4 months), compared to 24.8 months for the HR+/HER2? subtype, 19.8 months for the HR?/HER2+ subtype and 8.8 months for the TN subtype (P < 0.0001). In the multivariate analysis, subtype was an independent prognostic factor, as were initial site of metastases and metastatic-free interval. The HR+/HER2+ subtype was associated with the longest survival after diagnosis of distant metastases. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|